Production (Stage)
Nexien BioPharma, Inc.
NXEN
$0.0145
$0.00552.63%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 118.30K | 119.90K | 109.30K | 155.60K | 157.20K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 118.30K | 119.90K | 109.30K | 155.60K | 157.20K |
| Operating Income | -118.30K | -119.90K | -109.30K | -155.60K | -157.20K |
| Income Before Tax | -188.10K | -211.20K | -196.20K | -239.10K | -246.20K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.19 | -0.21 | -0.20 | -0.24 | -0.25 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -188.10K | -211.20K | -196.20K | -239.10K | -246.20K |
| EBIT | -118.30K | -119.90K | -109.30K | -155.60K | -157.20K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 280.73M | 276.34M | 270.68M | 264.78M | 259.79M |
| Average Diluted Shares Outstanding | 280.73M | 276.34M | 270.68M | 264.78M | 259.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |